Navigation Links
NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
Date:12/12/2010

rian cancer and now in metastatic breast cancer.  This clinical benefit we've observed in tumor settings, where a highly active topoisomerase 1 inhibitor could be extremely useful, makes us very excited about the future of NKTR-102."

Side effects were generally manageable with dose-limiting toxicity consisting primarily of Grade 3 diarrhea (20-23%) typically occurring after three months of therapy for both schedules.  Only one patient of 70 patients treated with NKTR-102 experienced Grade 2 alopecia and no patient experienced grade 3 or 4 neuropathy.  Both neuropathy and alopecia are significant adverse events commonly associated with standard breast cancer therapies [Safety Tables, Figures D and E].

SABCS PresentationThe presentation (P6-11-01) made today at the SABCS 2010 meeting can be found on Nektar's website at http://www.nektar.com/product_pipeline/oncology_nktr-102.html:

  • Awada et. al., "Significant Efficacy in a Phase 2 Study of NKTR-102, a Novel Polymer Conjugate of Irinotecan, in Patients with Pre-Treated Metastatic Breast Cancer (MBC)"

  • Nektar to Host Investor and Analyst Call/Webcast During SABCSThe call will include a webcast with slide presentation of the data and a summary review by Howard W. Robin, Nektar President and CEO.  The call will feature a review of the data by Dr. Ahmad Awada, Head of the Medical Oncology Clinic at the Institut Jules Bordet in Brussels, Belgium.  The webcast can be accessed live from the home page of Nektar's website at www.nektar.com.Date and Time:  Sunday, December 12, 2010, 9:00 a.m. – 10:00 a.m. Central Time  To access the audio conference call, follow these instructions:  Dial: 866-713-8310 (U.S.); (617) 597-5308 (international) Passcode: 36236932 (Nektar is the host)To access the live webcast, please log
    '/>"/>

    SOURCE Nektar Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
    2. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
    3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
    4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
    5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
    6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
    7. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
    8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
    9. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
    10. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
    11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/27/2015)... EAST RUTHERFORD, N.J. , May 27, 2015  Cambrex ... Gregory Sargen , Executive Vice President and Chief Financial Officer, ... June 3, 2015 at 8:00 a.m. EDT in ... webcast and slide presentation can be accessed from the Cambrex ... "Webcasts & Presentations", and a replay will be available for ...
    (Date:5/27/2015)... HANOVER, N.J. , May 27, 2015 /PRNewswire/ ... oncology portfolio in 21 medicines and 11 investigational ... the upcoming American Society of Clinical Oncology (ASCO) ... of the European Hematology Association (EHA), June 11-14. ... variety of cancer types, including melanoma, lung, breast, ...
    (Date:5/27/2015)... , May 25, 2015 Research and Markets ... the "Research and Future Development Trend Forecast of ... At present, there are 35,600 dialysis centers ... ratio are large due to the different regional operating ... centers in other Asian countries are operated by state-owned ...
    Breaking Medicine Technology:Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 2Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 3Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 4Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 5Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 6Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 7Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 8China Dialysis Market Report: Research and Future Development Trends and Forecasts 2015-2020 2
    ... the Consumer Healthcare Products Association (CHPA), announced Tammy Walsh as ... campaign to raise awareness of teen cough medicine ... boys and a high school math teacher from Northport, N.Y., ... substance abuse. Millions of Americans use medicines ...
    ... Dec. 15, 2011 Intellect Neurosciences, Inc. (OTCBB: ... and development of disease-modifying therapeutic agents for the ... today that it has filed an appeal regarding ... (EPO) to revoke the company,s ANTISENILIN® patents. The ...
    Cached Medicine Technology:CHPA's Five Moms Campaign to Stop Medicine Abuse Welcomes New Mom Tammy Walsh 2CHPA's Five Moms Campaign to Stop Medicine Abuse Welcomes New Mom Tammy Walsh 3Intellect Neurosciences Files Appeal in Europe in Response to Opposition Proceedings Instituted by Elan Pharmaceuticals and Wyeth/Pfizer 2Intellect Neurosciences Files Appeal in Europe in Response to Opposition Proceedings Instituted by Elan Pharmaceuticals and Wyeth/Pfizer 3
    (Date:5/27/2015)... 2015 Difass USA, a modern supplement ... with its first three flagship products, Dormiva™, Relaxiva™ and ... through http://www.difassusa.com . , A restful night’s ... but some people struggle with getting the full amount ... sleep aid designed to help you fall asleep and ...
    (Date:5/27/2015)... (PRWEB) May 27, 2015 On June ... advertising agency, will partner with LifeSource to host Donate ... will take place in a LifeSource donor coach outside ... to 4:00 p.m. , Demand for whole blood units ... Illinois, during the summer months. LifeSource requires approximately 1,000 ...
    (Date:5/27/2015)... Genius Monkey is pleased to announce ... technology, they have boosted sales for the Utah Honda ... level for seven Utah-based dealers. , Until recently, ... radio media. In 2014 the Utah Honda dealers changed ... Genius Monkey , shifted their marketing campaigns more towards ...
    (Date:5/27/2015)... 27, 2015 “Heroin has never been more ... overdoses are coming from,” says Harford County Sheriff Jeff Gahler, ... 8th. In the surging heroin related incidents in Baltimore, police ... education to prevent heroin addiction and subsequent abuse before it ... Drug Rehab Baltimore is a drug and alcohol rehab facility ...
    (Date:5/27/2015)... 2015 SmarterSkin, http://www.smarterskindermatology.com , is taking ... test that makes it easier for patients to find skin ... , Dr. Sejal Shah is a cosmetic dermatologist based in ... offer the test. This revolutionary DNA test uses 16 genetic ... aging: , 1. Firmness and elasticity , 2. ...
    Breaking Medicine News(10 mins):Health News:Supplement Brand Difass USA Launches in the U.S. with Three Flagship Products Designed to Bring Balance Back to Your Life 2Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:Genius Monkey Boosts Utah Honda Dealers Website Traffic 142% 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 3Health News:SmarterSkin Dermatology is Now Offering Skin DNA Analysis 2
    ... ... Accident Helpline warns of the dangers of cycling injuries and urges caution on the roads ... (PRWEB) June 14, 2010 -- National Accident ... now the improving weather is seeing an increasing number of people take to their bikes, often ...
    ... ... non-smoking environment in all 231 guest rooms and 17,000 sq feet of meeting space, effective ... Silver ... has taken one more step to “going green”, effective June 14 the Hotel will be ...
    ... before age 18 are much more likely as adults to ... injuring their partners, according to a new study. This ... intervention with suicidal teens. It is based on data from ... ages 10 to 32, and their romantic partners who participated ...
    ... ... Seconds , ... Heartbreaking is the only way to describe Dan McGehee’s third attempt at the 100-mile cycling ... his daughter Hope was born. Today, he missed the record by only 4 minutes and 57 ...
    ... ... to announce the relaunch of their website personalcarewholesaler.com, due to popular demand for an ... website offers wholesale pricing on thousands of personal care products. , ... (PRWEB) June 13, 2010 -- Personal ...
    ... danger to the blood supply, but urge more research , SATURDAY, ... and Human Services panel of experts on Friday voted to uphold ... more research on the controversial issue. , The current policy -- ... AIDS crisis -- prevents any man who since 1977 has had ...
    Cached Medicine News:Health News:Break The Injury Cycle, Says National Accident Helpline 2Health News:Teen boys who attempted suicide more like to abuse partners as adults 2Health News:Teen boys who attempted suicide more like to abuse partners as adults 3Health News:American Doctor Misses World Cycling Record by 4 minutes, 57 Seconds 2Health News:Wholesale Pricing on Health & Beauty Products Now Available Nationwide at PersonalCareWholesaler.com 2Health News:U.S. Panel Upholds Ban on Gay Men as Blood Donors 2Health News:U.S. Panel Upholds Ban on Gay Men as Blood Donors 3
    ...
    Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
    Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
    ... continues the "Consensus Concept" approach to design ... experience of a Scientific Advisory Board. The ... incorporates state-of-the-art features. Consensus Knee implants are ... stability and allow near normal kinematics. The ...
    Medicine Products: